In compliance with Order S.O. 5690(E) dated 17th October 2026 issued by the National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Government of India, under Paragraph 19 of the Drugs (Prices Control) Order, 2013, the trade margin on specified non-scheduled anti-cancer medicines has been capped at 30%. Accordingly, RPG LIFE SCIENCES LTD. has reduced the MRP of the following products. The revised MRPs will be effective from 9th November 2026.
| Sl. No. | Brand Name | Drug | Strength & Dosage Form | Pack Size | Current MRP (₹)(incl. of GST) | Revised MRP (₹)Effective from 9th Nov 2026 |
|---|---|---|---|---|---|---|
| 1 | Abitate 250 mg Tablet | Abiraterone acetate | 250mg (Tablet) | 120 Nos | ₹25,883.24 | ₹5,261.00 |
| 2 | Abitate 500mg | Abiraterone acetate | 500mg (Tablet) | 60 Nos | ₹25,500.00 | ₹5,249.00 |
| 3 | Abitate U 250mg | Abiraterone acetate | 250mg (Tablet) | 120 Nos | ₹37,417.36 | ₹6,278.00 |
| 4 | Abitate U 500mg | Abiraterone acetate | 500mg (Tablet) | 60 Nos | ₹25,500.00 | ₹5,246.00 |
| 5 | ACALBRIGHT 100mg | Acalabrutinib | 100mg (Capsule) | 30 Nos | ₹17,999.00 | ₹7,962.00 |
| 6 | ANARZOLE | Anastrazole | 1mg (Tablet) | 10 Nos | ₹695.76 | ₹73.00 |
| 7 | ARPRIDE 150mg | Olaparib | 150mg (Tablet) | 60 Nos | ₹19,500.00 | ₹11,999.00 |
| 8 | AZAPLAST 100MG INJ | Azacitidine | 100mg (Injection) | 1 Vial | ₹5,088.14 | ₹1,279.00 |
| 9 | Debrumab 60 mg | Denosumab | 60mg (Injection) | 1ml pfs | ₹22,031.25 | ₹5,941.00 |
| 10 | Denbri | Denosumab | 60mg (Injection) | 1ml pfs | ₹29,312.60 | ₹7,239.00 |
| 11 | Densurank 60 mg | Denosumab | 60mg (Injection) | 1ml pfs | ₹29,315.62 | ₹7,568.00 |
| 12 | Enuta | Enzalutamide | 40mg (Capsule) | 28 Nos | ₹6,578.20 | ₹2,232.00 |
| 13 | ENUTA 160MG 7's | Enzalutamide | 160mg (Capsule) | 7 Nos | ₹6,578.20 | ₹3,725.00 |
| 14 | EnzaMate 160mg | Enzalutamide | 160mg (Tablet) | 7 Nos | ₹6,578.20 | ₹3,134.00 |
| 15 | Enzamate 40 mg | Enzalutamide | 40mg (Tablet) | 7 Nos | ₹6,578.20 | ₹2,212.00 |
| 16 | Erubin 50 mg Inj 1's | Epirubicin | 50mg (Injection) | 1 Vial | ₹960.63 | ₹629.00 |
| 17 | Fulbreca 1's | Fulvestrant | 50mg (Injection) | 5ml Vial | ₹26,072.16 | ₹5,491.00 |
| 18 | Ivzumab 100 mg | Bevacizumab | 100mg (Injection) | 1 Vial | ₹26,621.75 | ₹4,493.00 |
| 19 | Ivzumab 400 mg | Bevacizumab | 400mg (Injection) | 1 Vial | ₹69,852.12 | ₹13,512.00 |
| 20 | Palbopro | Palbociclib | 125mg (Capsule) | 21 Nos | ₹40,421.33 | ₹2,720.00 |
| 21 | Peg Frastim | Pegfilgrastim | 6mg (Injection) | 1ml pfs | ₹6,660.85 | ₹1,807.00 |
| 22 | PEMEXAR 100 MG | Pemetrexed | 100mg (Injection) | 1 Vial | ₹1,892.98 | ₹468.00 |
| 23 | PEMEXAR 500 MG | Pemetrexed | 500mg (Injection) | 1 Vial | ₹7,050.56 | ₹1,219.00 |
Ashok Nair
Managing Director
RPG Life Sciences Ltd.
Date: 24/10/2026
Place: Mumbai